Follow
Professor Andrew J Pollard
Professor Andrew J Pollard
Verified email at paediatrics.ox.ac.uk
Title
Cited by
Cited by
Year
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK
M Voysey, SAC Clemens, SA Madhi, LY Weckx, PM Folegatti, PK Aley, ...
The Lancet 397 (10269), 99-111, 2021
36252021
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
PM Folegatti, KJ Ewer, PK Aley, B Angus, S Becker, ...
The Lancet 396 (10249), 467-478, 2020
20862020
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial
MN Ramasamy, AM Minassian, KJ Ewer, AL Flaxman, PM Folegatti, ...
The Lancet 396 (10267), 1979-1993, 2020
11362020
Efficacy of the ChAdOx1 nCoV-19 Covid-19 vaccine against the B. 1.351 variant
SA Madhi, V Baillie, CL Cutland, M Voysey, AL Koen, L Fairlie, ...
New England Journal of Medicine 384 (20), 1885-1898, 2021
10352021
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four …
M Voysey, SAC Clemens, SA Madhi, LY Weckx, PM Folegatti, PK Aley, ...
The Lancet 397 (10277), 881-891, 2021
8862021
Evidence of escape of SARS-CoV-2 variant B. 1.351 from natural and vaccine-induced sera
D Zhou, W Dejnirattisai, P Supasa, C Liu, AJ Mentzer, HM Ginn, Y Zhao, ...
Cell 184 (9), 2348-2361. e6, 2021
8162021
Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deployment
OJ Wouters, KC Shadlen, M Salcher-Konrad, AJ Pollard, HJ Larson, ...
The Lancet 397 (10278), 1023-1034, 2021
7052021
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B. 1.1. 7): an exploratory analysis of a randomised controlled trial
KRW Emary, T Golubchik, PK Aley, CV Ariani, B Angus, S Bibi, B Blane, ...
The Lancet 397 (10282), 1351-1362, 2021
5132021
Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection
S Feng, DJ Phillips, T White, H Sayal, PK Aley, S Bibi, C Dold, M Fuskova, ...
Nature medicine 27 (11), 2032-2040, 2021
4992021
Reduced neutralization of SARS-CoV-2 B. 1.617 by vaccine and convalescent serum
C Liu, HM Ginn, W Dejnirattisai, P Supasa, B Wang, A Tuekprakhon, ...
Cell 184 (16), 4220-4236. e13, 2021
4932021
What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2
SH Hodgson, K Mansatta, G Mallett, V Harris, KRW Emary, AJ Pollard
The lancet infectious diseases 21 (2), e26-e35, 2021
4772021
Maintaining protection against invasive bacteria with protein–polysaccharide conjugate vaccines
AJ Pollard, KP Perrett, PC Beverley
Nature Reviews Immunology 9 (3), 213-220, 2009
4722009
Antibody evasion by the P. 1 strain of SARS-CoV-2
W Dejnirattisai, D Zhou, P Supasa, C Liu, AJ Mentzer, HM Ginn, Y Zhao, ...
Cell 184 (11), 2939-2954. e9, 2021
4652021
T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial
KJ Ewer, JR Barrett, S Belij-Rammerstorfer, H Sharpe, R Makinson, ...
Nature medicine 27 (2), 270-278, 2021
3772021
A guide to vaccinology: from basic principles to new developments
AJ Pollard, EM Bijker
Nature Reviews Immunology 21 (2), 83-100, 2021
3722021
Reduced neutralization of SARS-CoV-2 B. 1.1. 7 variant by convalescent and vaccine sera
P Supasa, D Zhou, W Dejnirattisai, C Liu, AJ Mentzer, HM Ginn, Y Zhao, ...
Cell 184 (8), 2201-2211. e7, 2021
3642021
A CD8+ T cell transcription signature predicts prognosis in autoimmune disease
EF McKinney, PA Lyons, EJ Carr, JL Hollis, DRW Jayne, LC Willcocks, ...
Nature medicine 16 (5), 586-591, 2010
3612010
COVID-19 vaccine hesitancy in the UK
D Freeman, BS Loe, A Chadwick, C Vaccari, F Waite, L Rosebrock, ...
The Oxford coronavirus explanations, attitudes, and narratives survey …, 2020
3602020
SARS-CoV-2 Omicron-B. 1.1. 529 leads to widespread escape from neutralizing antibody responses
W Dejnirattisai, J Huo, D Zhou, J Zahradník, P Supasa, C Liu, ...
Cell 185 (3), 467-484. e15, 2022
3562022
Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization …
N Gossger, MD Snape, LM Yu, A Finn, G Bona, S Esposito, N Principi, ...
Jama 307 (6), 573-582, 2012
3472012
The system can't perform the operation now. Try again later.
Articles 1–20